

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/842,316 Applicant(s)

Kostenis et al.

Examiner

John Ulm

Art Unit 1646



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
	for Reply	
	ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE1 MONTH(S) FROM
	MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however, may a reply be timely filed after SIX (6) MONTHS from the
mailing	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within th	
- If NO	period for reply is specified above, the maximum statutory period will apply a	and will expire SIX (6) MONTHS from the mailing date of this communication.
	to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of t	
	patent term adjustment. See 37 CFR 1.704(b).	
Status 1) 🗌	Pagagaive to communication/s) filed as	
2a) 🗆	Responsive to communication(s) filed on This action is FINAL . 2b) X This act	
·		
3) 📙	closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11: 453 Q.G. 213
Disposi	tion of Claims	2.0,
· _		is/are-pending-in-the-application.
		is/are withdrawn from consideration.
_	Claim(s)	
6) 🗆	Claim(s)	
7) 🗆	Claim(s)	
_		are subject to restriction and/or election requirement.
	ation Papers	are subject to restriction analysis allocator requirement.
	The specification is objected to by the Examiner.	
10)		a) accepted or b) objected to by the Examiner.
	Applicant may not request that any objection to the d	
11)		is: a) approved b) disapproved by the Examiner.
,_	If approved, corrected drawings are required in reply t	
12)	The oath or declaration is objected to by the Exami	ner.
Priority	under 35 U.S.C. §§ 119 and 120	•
13)□	Acknowledgement is made of a claim for foreign pr	riority under 35 U.S.C. § 119(a)-(d) or (f).
a) 🗀	☐ All b)☐ Some* c)☐ None of:	
	1. \square Certified copies of the priority documents hav	e been received.
	2. \square Certified copies of the priority documents hav	e been received in Application No
:	3. Copies of the certified copies of the priority de application from the International Bures	ocuments have been received in this National Stage
*S	ee the attached detailed Office action for a list of the	
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
a) [$\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $	al application has been received.
15)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachm		
_	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
_	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
lnf-ال_اد	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6)

Application/Control Number: 09/842,316

Art Unit: 1646

Claims 1 to 32 are pending in the instant application.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1 to 14, 16 to 19 and 32, drawn to an isolated polynucleotide, vector, host cell and method of use, classified in class 435, subclass 69.1.
- II. Claim 15, drawn to an antibody, classified in class 530, subclass 388.22.
- III. Claim 20, drawn to a method of genetic diagnosis, classified in class 435, subclass6.
- IV. Claims 21 to 23, 26, 27 and 29, drawn to a ligand binding assay employing a recombinant cell expressing a heterologous cell surface receptor, classified in class 435, subclass 7.21.
- V. Claims 24 and 30, in so far as they are drawn to an agonist of unspecified constitution, classification undeterminable.
- VI. Claims 25, 28 and 30, in so far as they are drawn to an antagonist of unspecified constitution, classification undeterminable.
- VII. Claim 31, drawn to a pharmaceutical composition comprising a polypeptide, classified in class 514, subclass 2.

The inventions are distinct, each from the other because:

The polynucleotide of invention I, the antibody of invention II, the agonist of invention V, the antagonist of invention VI, and the polypeptide on invention VII are five different chemical compounds each of which can be made and used without the others. Lack of unity is shown by

Application/Control Number: 09/842,316

Art Unit: 1646

the fact that these five different compound do not share a common utility which is based upon a common structural feature lacking from the prior art.

Invention I is related to each of inventions III and IV as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the processes of inventions III and IV are materially different because they achieve different objectives by different steps. Further, invention I includes a process of employing the recombinant cell included therein to produce a heterologous polypeptide, which is a process that is materially different from the method of genetic diagnosis that is invention III or the binding assay of invention IV.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Art Unit: 1646

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1800